Dr. Merit Cudkowicz, MD
Claim this profileMore about Merit Cudkowicz, MD
Clinical Trial Related
5 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Merit Cudkowicz, MD has experience with
- ABBV-CLS-7262
- CNM-Au8
- Pridopidine
- SLS-005 Trehalose
- Verdiperstat
- Zilucoplan
Breakdown of trials Merit Cudkowicz, MD has run
Amyotrophic Lateral Sclerosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Merit Cudkowicz, MD specialize in?
Merit Cudkowicz, MD focuses on Amyotrophic Lateral Sclerosis and other conditions. In particular, much of their work with Amyotrophic Lateral Sclerosis has involved treating patients, or patients who are undergoing treatment.
Is Merit Cudkowicz, MD currently recruiting for clinical trials?
No, Merit Cudkowicz, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Merit Cudkowicz, MD has studied deeply?
Yes, Merit Cudkowicz, MD has studied treatments such as ABBV-CLS-7262, CNM-Au8, Pridopidine.
What is the best way to schedule an appointment with Merit Cudkowicz, MD?
Apply for one of the trials that Merit Cudkowicz, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.